CS
RGLS

Candriam SCA’s Regulus Therapeutics RGLS Stock Holding History

Candriam SCA’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-4,167
Closed -$330K – 836
2018
Q2 		$330K Hold
4,167
– – 0.01% 728
2018
Q1 		$359K Hold
4,167
– – 0.01% 711
2017
Q4 		$520K Sell
4,167
-833
-17% -$105K 0.01% 670
2017
Q3 		$750K Buy
+5,000
New +$629K 0.01% 611
2015
Q2 		– Sell
-317
Closed -$644K – 656
2015
Q1 		$644K Sell
317
-1,350
-81% -$2.93M 0.01% 510
2014
Q4 		$3.21M Buy
+1,667
New +$2.96M 0.07% 298

Other funds holding RGLS

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Ascend Capital Orinda, California $1.99B AUM 10.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Candriam SCA's RGLS Position: Q3 2018 in Review

Candriam SCA sold out of Regulus Therapeutics (RGLS) in Q3 2018, closing a stake of 4,167 shares — an estimated $330K sold.

Candriam SCA first reported a position in RGLS in Q4 2014 and held it in 6 quarters. The position peaked at $3.21M in Q4 2014. 36 funds tracked by Wall St. Rank hold RGLS as of Q3 2018.

  • Candriam SCA reported no remaining Regulus Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Candriam SCA sold 4,167 Regulus Therapeutics shares in Q3 2018, an estimated $330K.
  • Candriam SCA first reported a position in Regulus Therapeutics in Q4 2014 and held it in 6 quarters.
  • Candriam SCA's Regulus Therapeutics position peaked at $3.21M in Q4 2014.
  • 36 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q3 2018.

Based on Candriam SCA's 13F filing for Q3 2018, filed 7 Nov 2018.